ArticleAmerican journal of cancer research2025
Association of red blood cells, D-dimer, and 13-(S)-HODE with cancer-related ischemic stroke: a case-control study.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Stroke secondary to cancer-associated coagulopathy: a systematic review.Journal of neurology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the clinical characteristics of CRIS and potential laboratory indicators. Acute ischemic stroke (AIS) patients were retrospectively enrolled and categorized into two groups: a cancer-related ischemic stroke (CRIS) group (n = 41) and a non-cancer ischemic stroke group (NC-IS) (n = 213). Baseline characteristics were balanced using 1:1 propensity score matching, adjusting for age, sex, and comorbidities, resulting in 41 patients per group. Serum levels of 13-(S)-hydroxyoctadecadienoic acid [13-(S)-HODE] and nine routine laboratory indicators were measured. Univariate and multivariate logistic regression identified CRIS-associated indicators. Independently associated indicators were evaluated using ROC curve analysis. Additionally, cancer patients without stroke (CNSP, n = 40) and healthy controls (NC, n = 41) were matched to compare routine indicators. Respiratory (34.1%) and digestive (29.3%) cancers were the most common in CRIS patients. Stroke occurred within six months of cancer diagnosis in 36.6% of patients, and 75.6% had multifocal cortical-subcortical infarctions. Multivariate regression confirmed that decreased red blood cells (RBCs) (OR = 0.444, 95% CI: 0.205-0.961), elevated D-dimer (OR = 2.41, 95% CI: 1.67-3.48), and decreased 13-(S)-HODE (OR = 3.20, 95% CI: 1.92-5.33) were independent risk factors for CRIS. The AUCs for the three indicators and the combined model were: RBC, 0.642; D-dimer, 0.739; 13-(S)-HODE, 0.722; combined model, 0.819 (95% CI: 0.729-0.908). CRIS patients had significantly higher D-dimer than CNSP patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.